Clinical Trial Update: FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel [Phase 2]

View source ↗

Summary

Phase 2 trial of durvalumab combined with Carboplatin/Paclitaxel in squamous cell carcinoma of the head and neck has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Durvalumab (durvalumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Centre Leon Berard | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: COMPLETED